Working... Menu
Trial record 1 of 1 for:    NCT00490529
Previous Study | Return to List | Next Study

Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00490529
Recruitment Status : Completed
First Posted : June 22, 2007
Last Update Posted : January 23, 2018
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Ronald Levy, Stanford University

Brief Summary:
Mantle Cell Lymphoma is a sub-type of Non-Hodgkin's Lymphoma which is generally considered incurable with current therapy. Our goal is to accrue 59 patients who receive an autologous vaccine against their individual lymphoma after undergoing stem cell transplantation. Our hope is that vaccination will prolong the time which patients will stay in remission from their disease.

Condition or disease Intervention/treatment Phase
Lymphoma, Mantle-Cell Biological: CpG-MCL vaccine, primed T-cells Procedure: Autologous peripheral blood stem cell transplantation Procedure: CT scan Procedure: PET-CT scan Drug: PF-3512676 Drug: Rituximab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 61 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1-2 Study of a CpG-Activated Whole Cell Vaccine Followed by Autologous "Immunotransplant" for Mantle Cell Lymphoma
Study Start Date : August 2009
Actual Primary Completion Date : December 14, 2017
Actual Study Completion Date : December 14, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: "CpG-MCL" vaccine
Patients will initially receive three 'priming' CpG-MCL vaccinations in 21 days at 4-7 day intervals, followed by collection of "primed" T-Cells. Subsequently, within 72 hours of autologous hematopoetic cell transplant (AHCT)(standard of care procedure), the patient will receive his/her CpG-MCL vaccine and reinfusion of primed T cells ("immunotransplant"). At >/= 3 months after AHCT, when medically feasible, the patient will receive the final CpG-MCL vaccine. Regular follow-up research analysis of molecular residual disease will continue for 3 years or until disease progression.
Biological: CpG-MCL vaccine, primed T-cells
Other Name: CpG-activated, autologous tumor vaccine

Procedure: Autologous peripheral blood stem cell transplantation
Standard of Care
Other Name: Hematopoietic stem cell transplantation

Procedure: CT scan
Standard of Care
Other Name: X-ray computed tomography

Procedure: PET-CT scan
Standard of Care
Other Name: Poset emission tomography

Drug: PF-3512676
18 mg subcutaneous injection
Other Name: Pfizer

Drug: Rituximab
375 mg/m2 iv Standard of care.
Other Names:
  • Rituxan
  • MabThera

Primary Outcome Measures :
  1. The primary endpoint of the trial is freedom from molecular residual disease (MRD) at the landmark of one-year post-transplant. [ Time Frame: Samples for MRD analysis are collected every 3 months until one-year post transplant. ]
    After the one-year mark, samples for MRD analysis will be collected every 6 months for 3 years or until disease progression.

Secondary Outcome Measures :
  1. Secondary objectives are Time To Clinical Progression (TTP), and evaluation of anti-tumor immune responses after vaccination, and after immunotransplant. progression-free survival. [ Time Frame: 1 year, 3 years, 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria (at time of enrollment):

  • Patients must be newly diagnosed with mantle cell lymphoma, have an accessible disease site for excisional biopsy or have sufficient peripheral blood tumor to leukapherese at least 1.5 x 109 lymphoma cells in a single session.
  • By standard clinical criteria, be medically appropriate to receive rituximab and standard induction chemotherapy and high-dose chemotherapy with AHCT.
  • Patients must be HIV negative.
  • ECOG performance status 0, 1, or 2 or Karnofsky performance scale 50-100%.
  • Patients must be capable of signing an informed consent.

Exclusion Criteria:

  • Patients who are currently taking immunosuppressive medications.
  • Patients with severe psychological or medical illness.
  • Pregnant or lactating women.
  • At the discretion of the principal investigator if he/she feels that the patient is unable to safely complete the study. Specifically, patients must be considered medically eligible to undergo standard high dose chemotherapy and autologous stem cell transplantation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00490529

Layout table for location information
United States, California
Stanford University Medical Center
Stanford, California, United States, 94305
Sponsors and Collaborators
Ronald Levy
National Institutes of Health (NIH)
Layout table for investigator information
Principal Investigator: Ronald Levy Stanford University

Layout table for additonal information
Responsible Party: Ronald Levy, Professor, Stanford University Identifier: NCT00490529     History of Changes
Other Study ID Numbers: LYMNHL0040-BMT212
LYMNHL0040-BMT212 ( Other Identifier: OnCore )
IRB-05089 ( Other Identifier: Stanford IRB )
96940 ( Other Identifier: Stanford University Alternate IRB Approval Number )
First Posted: June 22, 2007    Key Record Dates
Last Update Posted: January 23, 2018
Last Verified: January 2018

Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Mantle-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Immunological
Antineoplastic Agents
Antirheumatic Agents